2024
Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapy
2016
Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures.
Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal Of The National Comprehensive Cancer Network 2016, 14: 1001-8. PMID: 27496116, PMCID: PMC5577560, DOI: 10.6004/jnccn.2016.0107.Peer-Reviewed Original ResearchConceptsDay of deathLife care expendituresLife careIntensive endCancer decedentsIntensive care unit admissionCare expendituresLife care interventionsCare unit admissionEmergency department visitsSEER-Medicare databaseLast monthProportion of decedentsHospital referral regionsExpenditure differencesHospital deathICU admissionUnit admissionDepartment visitsHospice enrollmentIntensive careHighest quintileLater chemotherapyHospice useLowest quintile